Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):269–274. doi: 10.1097/WAD.0000000000000029

Table 2.

Comparison of PREPARE participants who would vs. would not consider participation in a pharmacological prevention study.

Yes, would consider a
pharmacological
prevention trial (N=859)		 No, would not consider a
pharmacological
prevention trial (N=141)		 p value
Age, mean(SD) 67.8(7.7) 70.3(8.0) p<.001
Female (%) 84.1% 15.8% p<.05
Male (%) 90.4% 9.6%
Caucasian (%) 87.5% 12.3% p<.05
African American (%) 77.9% 22.1%
Positive Family History of
dementia (%)		 87.8% 12.2% ns
Negative Family History of
dementia (%)		 83.7% 16.3%
Cognitive status, % of High
Performers		 86.3% 13.7% p<.05
Cognitive status, % of Low
Performers		 85.3% 14.7%

Independent samples t-test was used to compare differences in age. Pearson χ2 test was used to compare difference in gender, race, family history of dementia, and cognitive status.